BiotechTube

Vandetanib 300 mg

Pre-clinicalCompleted
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Symptomatic, Aggressive, Sporadic, Unresectable, Locally

Conditions

Symptomatic, Aggressive, Sporadic, Unresectable, Locally, Advanced/Metastatic Medullary Thyroid Cancer (MTC)

Trial Timeline

Feb 17, 2014 → Jun 18, 2020

NCT ID
NCT01945762

About Vandetanib 300 mg

Vandetanib 300 mg is a pre-clinical stage product being developed by Sanofi for Symptomatic, Aggressive, Sporadic, Unresectable, Locally. The current trial status is completed. This product is registered under clinical trial identifier NCT01945762. Target conditions include Symptomatic, Aggressive, Sporadic, Unresectable, Locally, Advanced/Metastatic Medullary Thyroid Cancer (MTC).

What happened to similar drugs?

3 of 17 similar drugs in Symptomatic, Aggressive, Sporadic, Unresectable, Locally were approved

Approved (3) Terminated (4) Active (10)
❌Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
🔄ISV-305Sun PharmaceuticalPhase 3
🔄rabeprazole sodium + PlaceboEisaiPhase 3
🔄Esomeprazole + Matching placeboAstraZenecaPhase 3
🔄Pasireotide + OctreotideNovartisPhase 3
✅valsartanNovartisApproved
🔄Apixaban + Standard of carePfizerPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01945762Pre-clinicalCompleted

Competing Products

20 competing products in Symptomatic, Aggressive, Sporadic, Unresectable, Locally

See all competitors
ProductCompanyStageHype Score
Sodium hyaluronate + placebo injectionDaiichi SankyoPhase 3
32
ISV-305Sun PharmaceuticalPhase 3
40
rabeprazole sodium + PlaceboEisaiPhase 3
40
Verinurad + Febuxostat + DapagliflozinAstraZenecaPhase 2
35
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
32
Esomeprazole + Matching placeboAstraZenecaPhase 3
40
DFV890 + PlaceboNovartisPhase 2
35
Omalizumab + Omalizumab + PlaceboNovartisPhase 2
35
Pasireotide + OctreotideNovartisPhase 3
40
TegaserodNovartisPhase 2
35
valsartanNovartisApproved
43
Atorvastatin - Cholestyramine - SitosterolPfizerPre-clinical
26
Epoetin biosimilarPfizerPre-clinical
26
Apixaban + Standard of carePfizerPhase 3
40
Azithromycin plus chloroquinePfizerPhase 3
32
MavacamtenBristol Myers SquibbApproved
50
Aficamten + PlaceboSanofiPhase 3
44
REGN7508 + Acetylsalicylic Acid (ASA) + PlaceboRegeneron PharmaceuticalsPhase 3
47
Rivaroxaban + PlaceboBayerPhase 3
37
Droxidopa capsules + Placebo capsulesLundbeckApproved
40